---
title: "letter medication regimens homelessness"
year: 2023
month: 08
journal: "American Family Physician"
volume: "108"
issue: "08"
pages: ""
doi: ""
pmid: ""
source: "PDF Extraction"
pdf_available: true
original_pdf: "2023-08-letter-medication-regimens-homelessness.pdf"
extracted_date: "2025-08-10"
keywords: []
evidence_level: ""
clinical_significance: ""
---

# letter medication regimens homelessness

                                               Letters to the Editor
Importance of Simplifying Medication Regimens                                      of twice-daily carvedilol (Coreg). Also, I instruct patients
for Patients Experiencing Homelessness                                             to take loop diuretics only when they have reliable access
                                                                                   to restrooms.
To the Editor: I read the article by Dr. Lanham and col-                             These are small interventions and do little to address the
leagues with interest.1 I commend the authors for their                            structural foundations of the housing crisis in the United
cogent overview of medical care for people experiencing                            States, but they are important in the day-to-day care of
homelessness, which represents a growing crisis within the                         patients who find themselves marginalized and stigmatized
United States health care system.                                                  by broader society.
   I would like to underscore the importance of the authors’
specific considerations for simplifying medication regi-                             Editor’s Note: This letter was sent to the authors of “Care
mens in this population whenever possible. My colleagues                             of People Experiencing Homelessness,” who declined to
and I conducted a qualitative study of individuals with                              reply.
heart failure experiencing homelessness in one U.S. city,
examining participants’ interactions with the health care                          Akshay Pendyal, MD, MHS, FACC
                                                                                   Durham, N.C.
system.2 Heart failure is a common condition involving                             Email: akshay.pendyal@duke.edu
intensive self-management behaviors, especially adherence
to medications. New evidence-based treatments for heart                            Author disclosure: No relevant financial relationships.
failure continue to emerge, and the medication regimens                            References
have become increasingly complex.3 Complex regimens are
                                                                                    1. Lanham JS, White P, Gaffney B. Care of people experiencing homeless-
a known barrier to medication adherence in patients with                               ness. Am Fam Physician. 2022;​106(6):​684-693.
heart failure.4                                                                     2. Pendyal A, Rosenthal MS, Spatz ES, et al. “When you’re homeless, they
   For participants in our study, homelessness engendered                              look down on you”:​a qualitative, community-based study of homeless
a pervasive sense of instability and a lack of routine. Rou-                           individuals with heart failure. Heart Lung. 2021;​50(1):​80-85.
                                                                                    3. Hauptman PJ. Medication adherence in heart failure. Heart Fail Rev.
tine plays a central role in the successful self-management                            2008;​1 3(1):​99-106.
of many chronic conditions such as heart failure.5 Individu-                        4. Forsyth P, Richardson J, Lowrie R. Patient-reported barriers to medi-
als in our sample expressed difficulty establishing a routine                          cation adherence in heart failure in Scotland. Int J Pharm Pract. 2019;​
involving heart failure medications. One participant said,                             27(5):​4 43-450.

“It’s hard to take the medication when you’re out there…                            5. Scotto CJ. The lived experience of adherence for patients with heart
                                                                                       failure. J Cardiopulm Rehabil. 2005;​25(3):​158-163.
I take 12 different types of medications…the only ones I                            6. Sadik A, Yousif M, McElnay JC. Pharmaceutical care of patients with
would take is the torsemide and spironolactone so I can get                            heart failure. Br J Clin Pharmacol. 2005;​60(2):​183-193.
[fluid] off of me.”
   This presents an opportunity for primary care clinicians
and specialists caring for individuals with heart failure who                      Corrections
are homeless. Simplifying medication regimens is associated                        Incorrect symbol. In the article “Alcohol Withdrawal Syn-
with improved medication adherence in heart failure.6 Such                         drome: Outpatient Management” (September 2021, p. 253),
an approach, when applied to patients with heart failure who                       Table 4 incorrectly used the > symbol instead of the ≥ symbol
are experiencing homelessness, may reduce the burden on                            in the next-to-last row (p. 259). It should have read, “Severe
this vulnerable population.                                                        and complicated withdrawal symptoms (CIWA-Ar ≥ 19).”
   As a cardiologist in a safety-net clinic treating patients                      The online version of this article has been corrected.
experiencing homelessness, I try to incorporate these
considerations into my clinical practice. I often preferen-                        Vaccination recommendation. In the Practice Guideline
tially prescribe once-daily metoprolol succinate instead                           “ACIP Approves 2023 Child/Adolescent and Adult Immu-
                                                                                   nization Schedules” (March 2023, p. 319), the recommended
  Email letter submissions to afplet@aafp.org. Letters should                      schedule for pneumococcal vaccination for adults younger
  be fewer than 400 words and limited to six references,                           than 65 years was not clearly stated. The first sentence of the
  one table or figure, and three authors. Letters submitted                        second paragraph in the Pneumococcal Vaccination section
  for publication in AFP must not be submitted to any other                        (p. 321) should have read, “For adults younger than 65 years
  publication. Letters may be edited to meet style and space
                                                                                   with certain risk factors (Table 22), either PCV15 and then
  requirements.
                                                                                   PPSV23 after eight weeks, or a single PCV20 are recom-
  This series is coordinated by Kenny Lin, MD, MPH, deputy
  editor.
                                                                                   mended.” The online version of this Practice Guideline has
                                                                                   been corrected.

118  American
Downloaded   from Family   Physician
                  the American  Family Physician website at www.aafp.org/afp.            © 2023 American AcademyVolume
                                                                                  Copyright
                                                                    www.aafp.org/afp                                     of Family108,
                                                                                                                                   Physicians.
                                                                                                                                       Number  For2theAugust
                                                                                                                                                  ◆   private, non-
                                                                                                                                                               2023
 commercial use of one individual user of the website. All other rights reserved. Contact copyrights@aafp.org for copyright questions and/or permission requests.
                                                         LETTERS TO THE EDITOR


Incorrect recommendation. In the article “Tuberculosis:                     infection in children and adolescents: testing and treatment.
Common Questions and Answers” (September 2022, p. 308),                     Pediatrics. 2021;148(6):e2021054663. In Table 2 (p. 310), one
the recommended cutoff age for interferon-gamma release                     of the cons listed for QuantiFERON-TB Gold+ should have
assay (IGRA) testing was listed incorrectly. In the first para-             read, “Not recommended for children younger than two
graph of the “What Are the Advantages and Disadvantages                     years*” with the following accompanying footnote: “Guide-
of TST vs. IGRA?” section, the second-to-last sentence                      lines from the Centers for Disease Control and Prevention
(p. 309) should have read, “Disadvantages of IGRA testing                   and the American Thoracic Society state five years and older,
include cost, and it is not recommended for use in children                 but the American Academy of Pediatrics guidelines state two
younger than two years.” An additional reference has been                   years and older.32” The online version of the article has been
added to the online version of this article for this sentence               corrected. ■
and for a footnote in Table 2: Nolt D, Starke JR. Tuberculosis

   TABLE 2

   Comparison of Tuberculosis Tests
   Test characteristic            Tuberculin skin test                        QuantiFERON-TB Gold+           T-SPOT.TB

   Format                         Purified protein derivative injected       Enzyme-linked immu-             Enzyme-linked immunosorbent
                                  intradermally;​patient must return         nosorbent assay using           spot test using peripheral blood
                                  in 48 to 72 hours for results              whole blood;​processed          mononuclear cells;​processed
                                                                             within 16 hours                 in eight to 24 hours (up to 32
                                                                                                             hours if T-Cell Xtend is used)

   Measurement                    Size of skin induration                    Interferon-gamma level          Interferon-gamma level

   Sensitivity (%)                68.9                                       94.1                            95.6

   Specificity (%)                59                                          97.3                           97.1

   Positive likelihood ratio         1.68                                    34.85                           32.97

   Negative likelihood ratio         0.595                                     0.029                          0.030

   Results affected by BCG        Yes                                        No                              No
   vaccination?

   Pros                           Lower cost                                 High specificity                High specificity
                                                                             Objective results               Objective results
                                                                                                             Only reacts to Mycobacterium
                                                                                                             tuberculosis, not other myco-
                                                                                                             bacterial strains

   Cons                           Requires at least two separate visits      Cost                            Cost
                                  Affected by BCG vaccination status         Availability                    Availability
                                  False-negative risk if recent live         Not recommended for             Potential for improper handling
                                  vaccination                                children younger than           and processing
                                  Subjective results                         two years*                      Not approved for children
                                  Misreading of skin test results                                            younger than two years*
                                                                                                             Different reactivity criteria in the
                                                                                                             United States, Canada, Europe

   BCG = bacillus Calmette-Guérin.
   *—Guidelines from the Centers for Disease Control and Prevention and the American Thoracic Society state five years and older, but the American
   Academy of Pediatrics guidelines state two years and older. 32
   Information from references 12, 13, and 32.




August 2023 ◆ Volume 108, Number 2                           www.aafp.org/afp                                    American Family Physician 119
